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Human lung tissue-resident NK cells (trNK cells) are likely to play an important role in host
responses towards viral infections, inflammatory conditions and cancer. However, detailed
insights into these cells are still largely lacking. Here we show, using RNA sequencing and
flow cytometry-based analyses, that subsets of human lung CD69+CD16− NK cells display
hallmarks of tissue-residency, including high expression of CD49a, CD103, and ZNF683, and
reduced expression of SELL, S1PR5, and KLF2/3. CD49a+CD16− NK cells are functionally
competent, and produce IFN-γ, TNF, MIP-1β, and GM-CSF. After stimulation with IL-15, they
upregulate perforin, granzyme B, and Ki67 to a similar degree as CD49a−CD16− NK cells.
Comparing datasets from trNK cells in human lung and bone marrow with tissue-resident
memory CD8+ T cells identifies core genes co-regulated either by tissue-residency, cell-type
or location. Together, our data indicate that human lung trNK cells have distinct features,
likely regulating their function in barrier immunity.
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Mucosal surfaces in the human lung are frequentlyexposed to microbes, environmental particles, andother forms of antigens. Consequently, the lung is often
subject to severe acute and chronic inflammatory diseases and
malignancies exemplified by allergies, asthma, microbial infec-
tions, and cancer, many of which are major causes of morbidity
and mortality. Tissue-resident lymphocytes that are located close
to the airways in the lung are exposed to many of these potentially
disease-causing agents and/or malignant cells. Depending on
their functional responses, they likely play important roles in the
pathogenesis of many of the above-mentioned diseases.
Human lung tissue-resident memory CD8+ T (TRM) cells have
been demonstrated to have a unique transcriptional profile1,2.
Furthermore, the frequency of TRM cells in tumors have been
shown to correlate positively with clinical outcome in lung
cancer3,4. Of note, exploitation of TRM cells is currently discussed
as a potential approach in human cancer immunotherapy5. In
contrast to TRM cells, surprisingly little is known about tissue-
resident NK (trNK) cells in human lung. Indeed, most of our
knowledge about human NK cells is still largely deduced from
ex vivo studies of NK cells derived from peripheral blood. NK
cells constitute an important part of the innate immune defense
with the capacity to kill virus-infected and malignant cells and
mediate immunoregulatory responses by releasing several
proinflammatory cytokines such as IFN-γ and TNF6. With
respect to human lung NK cells, they have been phenotypically
characterized to some extent and shown to be hyporesponsive
toward tumor target cell stimulation ex vivo7. They do, however,
respond to virus-infected target cells8, indicating that lung trNK
cells could be clinically relevant in pathological conditions.
Approximately 10% of CD56dimCD16+ NK cells and 75% of
CD56brightCD16− NK cells in the human lung express CD697.
CD69 has been demonstrated to inhibit the egress of T cells from
tissues by interfering with the sphingosine-1-phosphate receptor
(S1P1)9, and is therefore considered a hallmark marker of tissue-
resident lymphocytes. In addition, the integrins CD49a (α1
integrin) and CD103 (αE integrin) are involved in retaining
lymphocytes in tissues and, hence, identify TRM cells and trNK
cells10–12. CD49a binds to collagen IV, which is a main compo-
nent of the basement membrane of the blood–gas–barrier in the
lung but is largely absent in the lung parenchyma. CD103 binds
to E-cadherin, which is expressed by epithelial cells lining the
alveolar spaces and bronchial epithelium of the lung, as well as on
lung tumors of epithelial origin13. CD103+ CD8+ TRM cells have
been demonstrated to be located close to the epithelia in the
human lung14, hence, the expression of CD103 on tissue-resident
lymphocytes is indicative of their localization. Distinct tissue-
specific expression patterns of CD49a and CD103 have been
detected on NK cells in human liver15, tonsil16, and endome-
trium17, indicating that there are discrete subsets of trNK cells in
each of these organs. Moreover, recent studies of CD49a+ NK
cells in human liver have revealed subsets of Eomes−T-bet+ and
Eomes+T-betlow NK cells, identifying potentially distinct lineages
of CD49a+ trNK cells within this organ15,18,19. In contrast,
comparatively much less is known about the nature of human
trNK cells in many other tissues including the lung.
Here, we analyze phenotypic, transcriptional, and functional
traits of discrete NK cell subsets in the human lung with respect
to tissue-residency. We identify NK cell subsets with a gene and
protein-expression profile consistent with that of tissue-resident
lymphocytes, e.g., cell surface expression of CD69, CD49a, and
CD103. Comparisons of gene expression patterns in NK cells and
CD8+ T cells in different tissues reveal core genes co-regulated
either by tissue-residency, cell-type or location. Together, our
data demonstrate that CD69+ NK cells co-expressing CD49a and
CD103 display distinct hallmarks of tissue-residency with a
tissue-specific and functional signature. These findings contribute
to the understanding of lung tissue-associated barrier functions as
well as the role of trNK cells in lung pathologies, such as viral
infections and cancer.
Results
An NK cell subset in human lung expresses CD49a and CD103.
The majority of CD56brightCD16− NK cells and a subset of
CD56dimCD16+ NK cells in human lung expresses CD697, a
marker commonly expressed by tissue-resident lymphocytes. In
order to determine whether additional markers of tissue-
residency were expressed on human lung CD69+ NK cells, we
analyzed expression of the integrins CD49a and CD103 on these
cells (Fig. 1). NK cells were identified as live CD45+CD3−CD14−
CD19−CD56+ lymphocytes (Supplementary Fig. 1a). Both
CD49a and CD103 were expressed on a significant proportion of
CD16−CD69+ NK cells and to a lesser degree on CD16+CD69+
lung NK cells (Fig. 1a, b). In contrast, these molecules were
detected at very low frequency on NK cells isolated from per-
ipheral blood (Supplementary Fig. 1b). Furthermore, CD49a and
CD103 were commonly co-expressed (Fig. 1b, c), although sub-
sets of CD49a+CD103−CD69+ NK cells and, to a lesser extent,
CD49a−CD103+CD69+ NK cells were detected (Fig. 1b), in line
with a recent report8. The vast majority of CD69+CD49a+
CD103−, CD69+CD49a−CD103+, and CD69+CD49a+CD103+
NK cells lacked expression of CD16 (Fig. 1d, e). Conversely, the
vast majority of the CD49a+CD103−CD16−, CD49a−CD103+
CD16−, and CD49a+CD103+CD16− NK cells co-expressed
CD69, whereas only approximately 50% of CD49a−CD103−
CD16− NK cells co-expressed CD69 (Fig. 1f). However, in a few
donors CD49a and CD103 were co-expressed at a higher fre-
quency also on CD69+CD16+ lung NK cells (Fig. 1b). In these
donors, CD49a and CD103 were expressed predominantly by a
subset of CD56brightCD16+ NK cells (Supplementary Fig. 1d, e).
Furthermore, a subset of CD56dimCD16− NK cells accounted for
another minor population of lung NK cells expressing CD49a and
CD103 (Fig. S1d, e). On average, the CD69+CD49a+CD103−
CD16−, CD69+CD49a−CD103+CD16−, and CD69+CD49a+
CD103+CD16− NK cells together made up 20% of the total NK
cell population in lung. CD16+CD69− NK cells made up the
majority of NK cells in the human lung, as previously reported7
(Fig. 1g). The total frequencies of CD69+CD49a+
CD103−CD16−, CD69+CD49a−CD103+CD16−, and CD69+
CD49a+CD103+CD16− NK cells detected were independent of
clinical parameters, including medication and type of cancer of
patients from whom clinical samples were derived (Supplemen-
tary Fig. 2a–c). However, frequencies of these cells were higher in
the lungs of active smokers as compared to ex-smokers and non-
smokers (Supplementary Fig. 2d). Noteworthy, non-NK innate
lymphoid cells (ILCs), here defined as live CD45+CD14−
CD19−CD3−CD16−NKG2A−KIR−CD69+CD127+ lymphocytes
(Supplementary Fig. 1f), expressed substantially less CD49a and
CD103 compared to NK cells and CD8+ T cells in the human
lung (Fig. 1h, i). Since CD103+CD8+ TRM cells have previously
been shown to be located in or close to the lung epithelium where
ligands for both CD103 (E-cadherin) and CD49a (collagen) are
expressed, our data suggests that CD49a+CD103+ NK cells have
an intraepithelial location. In summary, we show that a sub-
stantial fraction of primarily CD16− NK cells co-express CD69,
CD49a, and CD103, and thus may represent trNK cells in human
lung.
Lung trNK cells segregate on protein and transcription level.
To characterize the subsets of CD16− NK cells in human lung, we
next analyzed protein expression on CD16− NK cell subsets
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defined by distinct patterns of expression of CD69, CD49a, and
CD103 (Fig. 2a–h). CD69+CD49a-CD103−CD16− (CD69sp),
CD69+CD49a+CD103−CD16−, and CD69+CD49a+CD103+
CD16− NK cells almost completely lacked expression of CD57
and expressed high levels of NKG2A (Fig. 2a, b). We however
noted that a fraction of the CD69−CD16− NK cell subset
expressed CD57 (Fig. 2b), indicating that this subset might
include CD56dimCD16+ NK cells that had downregulated
expression of CD16. In the subsequent analyses, we therefore
gated on CD57−NKG2A+ cells among the CD69−CD16− NK
cells (hereafter referred to as “CD69−CD16−” NK cells) to avoid
including CD56dim NK cells that had lost CD16 expression. As
expected, all CD16− NK cell subsets expressed higher levels of
CD56 compared to CD16+ NK cells (Fig. 2c, d). Next, we ana-
lyzed the expression of the chemokine receptors CXCR3 and
CXCR6, which have previously been shown to be important for
tissue-homing (Fig. 2c, d). While CXCR3 was highly expressed on
CD69−CD16−, CD69+CD49a+CD103−CD16−, and CD69+
CD49a+CD103+CD16− NK cells, levels were low on the
CD69spCD16− and CD56dimCD16+ NK cells. In contrast,
CXCR6 expression was modestly, but yet significantly, increased
on CD69+CD49a+CD103+CD16− compared to CD69−CD16−
NK cells (Fig. 2c, d). These results indicate potential differences in
the tissue-homing capacity between the NK cell subsets. Ex vivo,
all CD69+CD16− NK cell subsets analyzed (CD69sp, CD69+
CD49a+CD103− and CD69+CD49a+CD103+) expressed per-
forin, albeit at lower levels than CD16+ NK cells (Fig. 2e, f).
Finally, both the CD69− and CD69+ NK cell subsets expressed
Eomes, and, at lower levels, T-bet, identifying them as bona fide
NK cells (Fig. 2g, h).
To further characterize the subsets of CD16− NK cells, we
performed RNAseq analysis of four subsets of CD56+NKG2A+
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Fig. 1 CD69+CD16− NK cells in the human lung co-express CD49a and CD103. a Representative dot plots and b summary of data of CD49a and
CD103 expression on CD69+CD16− and CD69+CD16+ NK cells (n= 64). Mean ± SD is shown. c Linear regression analysis of CD49a and CD103 co-
expression on NK cells in human lung (n= 98). d Representative histogram and e summary of data of CD16 expression on CD69− (n= 20), CD69sp (n=
20), and CD69+CD49a+CD103− (n= 17), CD69+CD49a−CD103+ (n= 15) and CD69+CD49a+CD103+ (n= 19) NK cells in human lung. Mean ± SD is
shown. f Summary of data for CD69 expression on human lung CD49a−CD103−CD16− (orange), CD49a+CD103−CD16−, CD49a−CD103+CD16−, and
CD49a+CD103+CD16− (all blue) NK cells (n= 37). Mean ± SD is shown. g Frequency of NK cell subsets defined by the expression of CD16, CD69,
CD49a, and CD103 out of total NK cells (n= 37). Mean ± SD is shown h Percentages of CD49a+ and i CD103+ cells among CD127+ ILCs (defined as live
CD45+CD14−CD19−CD3−CD16−NKG2A−KIR−CD69+CD127+) (n= 19) and CD69+CD8+ T cells in the human lung (n= 23). Mean ± SD is shown.
Statistical analysis in b, f RM one-way ANOVA, Tukey’s multiple comparison test, Geisser-Greenhouse’s correction. *p < 0.05, **p < 0.005, ***p < 0.001,
****p < 0.0001; ns, non-significant; e Kruskall-Wallis test, Dunn’s multiple comparisons test. **p < 0.005, ****p < 0.0001; h, i Two-tailed Wilcoxon
matched-pairs signed rank test, ****p < 0.0001. Source data are provided as a Source Data file
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CD16− NK cells from human lung: CD69−, CD69+CD103−
CD49a− (CD69sp), CD69+CD49a+CD103−, and CD69+
CD49a+CD103+ NK cells (Fig. 2i–k, see Supplementary Fig. 1g
for gating strategy). In addition, we analyzed CD56dimCD16+
NKG2A+CD57− NK cells from the human lung as a reference
population (see Supplementary Fig. 1g for gating strategy).
Principal component analysis (PCA) revealed that the CD69+
CD49a+CD103− and the CD69+CD49a+CD103+ subsets were
clearly distinct from the CD69sp and CD69− subsets, as indicated
by separation along PC1 (Fig. 2i). Furthermore, the CD69sp and
CD69− subsets were separated along PC2 (Fig. 2i), showing that
also these populations were distinct from each other. As a
reference, CD56dimCD16+NKG2A+CD57− NK cells were
included in a separate PCA (Supplementary Fig. 3a). The latter NK
cells clearly separated from all CD16− subsets, in line
with previous studies comparing CD56dim and CD56bright NK
cells20–22.
Next, we analyzed differentially expressed genes between the
four different subsets. In this analysis, we identified 230
differentially expressed genes (adjusted p-value < 0.05, and more
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than one-fold log2 difference) between the different subsets
(Fig. 2j, k, and Supplementary data 1). The largest number of
differentially expressed genes was identified when comparing the
CD69+CD49a+CD103− and CD69+CD49a+CD103+ subsets
with the CD69− subset. In contrast, only a limited number of
genes were differentially expressed between the CD69+CD49a+
CD103− and CD69+CD49a+CD103+ subsets, and between the
CD69sp and CD69− subsets, respectively (Fig. 2j, k, Supplemen-
tary Fig. 3b, and Supplementary data 1). Both CD69+CD49a+
CD103− and CD69+CD49a+CD103+ subsets of NK cells
expressed higher levels of ITGA1 (CD49a), ZNF683 (Hobit),
RGS1, and RGS2, and lower levels of SELL (CD62L), S1PR5, and
KLF3 transcripts compared to the CD69−subset (Fig. 2k). All of
these genes have previously been described as hallmarks of CD8+
TRM cells and have been shown to be involved in tissue-
retention23. Furthermore, the CD69+CD49a+CD103+ NK cell
subset expressed significantly higher levels of ITGAE (CD103),
ITGB1 (CD29), and CXCR6, and lower levels of KLF2 compared
to the CD69− subset (Fig. 2k and Supplementary Fig. 3b).
Notably, the CD69+CD49a+CD103+ subset only differed from
the CD69+CD49a+CD103− subset with lower expression of a
handful of genes, including SELL, SATB1 and HSPA1A
(Supplementary Fig. 3b). Taken together, the gene expression
signatures of CD69+CD49a+CD103− and CD69+CD49a+
CD103+ NK cells strongly indicate that they represent trNK cells.
Since CD69 is commonly considered a hallmark marker of
tissue-resident lymphocytes, we additionally analyzed whether the
CD69sp subset in the lung also expressed genes associated with
tissue-residency despite the lack of CD49a and CD103. Relatively
few differentially expressed genes were, however, detected when
comparing the CD69sp and CD69−subsets with each other
(Fig. 2j, k and Supplementary Fig. 3b), although several of them
have been associated with tissue-residency, such as SELL, RGS1,
and ALOX5AP. In contrast, a substantially larger number of
differentially expressed genes were detected when comparing the
CD69sp and CD69+CD49a+CD103+ subsets, e.g., lower expres-
sion of RGS1, RGS2, and ZNF683, and higher expression of SELL,
KLF2, and S1PR5 in the former subset (Fig. 2j, k and
Supplementary Fig. 3b). This indicates that CD69spCD16−NK
cells in the human lung have a less distinct tissue-resident
phenotype.
In addition to the identification of genes directly involved in
tissue-retention, a number of genes involved in regulating NK cell
function were also differentially expressed in the CD69+
CD49a+CD103− and CD69+CD49a+CD103+ NK cell subsets
compared to the CD69−subset, including higher expression of
KLRF2 (NKp65), CD96, LAG3, and CTLA4 and lower expression
of KLRF1 (NKp80), IL18R1, IL18RAP, and IL7R (CD127) in the
former subsets (Fig. 2k, Supplementary Fig. 3b, and Supplemen-
tary data 1). Of note, the CD69sp subset differed from the
CD69−, CD69+CD49a+CD103−, and CD69+CD49a+CD103+
subsets with lower expression of GNLY (Granulysin) and GZMB
(Granzyme B) (Fig. 2k, Supplementary Fig. 3b), indicating that
CD69spCD16−NK cells have reduced cytotoxic capacity.
Transcription factors control the expression of a large number
of genes, and therefore differences in expression of transcription
factors are likely to reflect important differences in the biology of
NK cells. The CD69+CD49a+CD103− and CD69+CD49a+
CD103+ subsets indeed differed in their expression profile of a
number of transcription factors compared to the CD69−subset
(Fig. 2k and Supplementary Fig. 3b), further strengthening the
notion that these cells constitute a distinct population of cells. For
example, the CD69+CD49a+CD103−and CD69+CD49a+
CD103+ subsets had increased expression of ID3, STK16, and
RBPJ, and decreased expression of KLF3, SOX4, EGR1, and TCF7
compared to the CD69− NK cell subset (Fig. 2k and
Supplementary Fig. 3b). Moreover, the CD69+CD49a+CD103+
subset expressed higher levels of the transcription factors
ZNF331, IKZF3, CITED2, and IRF4, and lower levels of KLF2,
SMAD3, SATB1, RUNX3, MLX, ZNF600, and BACH2 compared
to the CD69−subset (Fig. 2k, Supplementary Fig. 3b, and
supplementary data 1).
Taken together, the combined gene and protein expression
analyses showed that CD69+CD49a+CD103−CD16− and
CD69+CD49a+CD103+CD16− NK cells were distinct from both
CD69spCD16− and CD69−CD16− NK cells, and had a
transcriptional signature indicative of tissue-residency in human
lung. In contrast, CD69spCD16− NK cells in human lung were
overall more similar to CD69−CD16− NK cells and, to a lesser
extent, expressed genes associated with tissue-residency.
TrNK cells differ between tissues and from CD8+ TRM cells.
Recently, the transcriptome of trNK cells in human bone marrow
was published20 and was found to share a transcriptional sig-
nature with human spleen CD8+ TRM cells1. It however remains
Fig. 2 Human CD69+CD16− lung NK cell subsets have unique characteristics. a Representative overlays and b summary of data of expression of NKG2A
and CD57 on CD16− human lung CD69−CD49a−CD103− (n= 20 for both), CD69sp (n= 20 for both), CD69+CD49a+CD103− (n= 14 and n= 13,
respectively), and CD69+CD49a+CD103+ (n= 17 and n= 15, respectively) NK cells. CD56dimCD16+ NK cells are shown for comparison (n= 20 and n=
19, respectively). Numbers in a indicate %NKG2A+ and %CD57+ NK cells, respectively. c Representative overlays and d summary of mean fluorescence
intensity (MFI) of CD56 (n= 18 for CD16−CD69−CD49a−CD103−NKG2A+CD57−, n= 21 for CD69+CD49a−CD103−CD16−, n= 16 for CD69+CD49a
+CD103−CD16−, n= 19 for CD69+CD49a+CD103+CD16−, and n= 20 for CD56dimCD16+), CXCR3 (n= 3) and CXCR6 (n= 7) on human lung CD69
−CD49a−CD103−NKG2A+CD57−, CD69sp, CD69+CD49a+CD103−, and CD69+CD49a+CD103+ NK cells within the CD16− subset. e Representative
overlay and f summary of MFI of perforin expression in CD16−CD69−CD49a−CD103−NKG2A+CD57−, CD69spCD16−, CD69+CD49a+
CD103−CD16−, CD69+CD49a+CD103+ CD16−, and CD69−CD49a−CD103−CD16+ NK cells in human lung (n= 5). CD127+CD161+ cells from lung
tissue are shown as a comparison (n= 5). g Representative overlays and h summary of MFI of Eomes (left panel) (CD16−CD69−CD49a−CD103−
NKG2A+CD57− (n= 5, other subsets n= 7) and T-bet (right panel) (CD16−CD69−CD49a−CD103−NKG2A+CD57− (n= 4, other subsets n= 6)
expression in CD16− human lung CD69−CD49a−CD103−NKG2A+CD57−, CD69sp, CD69+CD49a+CD103−, and CD69+CD49a+CD103+ NK cells.
Expression in CD16+CD69−CD49a−CD103− NK cells and non-NK cell ILCs (CD56−CD16−NKG2A−KIR−CD161+) are shown as a reference for Eomes
(n= 4), and T-bet (n= 6), respectively. i Principal component analysis based on 1,000 most variable genes across subsets. j Euler diagram based on the
230 differentially expressed genes (DEGs, p < 0.05, log2 fold change > 1) between CD69+CD49a+CD103+NKG2A+CD16−, CD69+CD49a+CD103−
NKG2A+CD16−, CD69spNKG2A+CD16− and CD69−NKG2A+CD16− NK cells. DEGs among CD69+CD49a+CD103+NKG2A+CD16− and CD69+
CD49a+CD103−NKG2A+CD16− were pooled in the analysis. k Heatmap of 142 DEGs (padj < 0.01, log2 fold change > 1) with genes ordered by hierarchical
clustering. Genes involved in regulation of tissue-residency, homing, and/or NK cell function are highlighted. Two replicates per donor and subsets are
shown. Significant DEGs identified using deSeq2. Colour scale depicts z-score. b, d, f, h Kruskal-Wallis test, Dunn’s multiple comparisons test, *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001. Means ± SD are shown. Source data are provided as a Source Data file
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unknown whether trNK cells are unique for their respective tissue
environment, and to what extent they share a common tran-
scriptional signature. We therefore next compared the profile of
differentially expressed genes in lung trNK cells (CD69+CD49a+
CD103+CD16− trNK cells versus CD69−CD16− NK cells), with
available published data on bone marrow trNK cells (CXCR6+
CD69+CD54+ trNK cells versus CXCR6−CD56bright NK cells)20,
as well as with CD8+ TRM cells in human lung and spleen
(CD69+CD45RA−CCR7− TRM cells versus CD69−
CD45RA−CCR7−CD8+ TEM cells)1. Out of the differentially
expressed genes detected in trNK cells in lung (padj < 0.05), a
substantial number were also differentially expressed in trNK cells
in bone marrow (Fig. 3a), as well as in CD8+ TRM cells in lung
(Fig. 3b). In contrast, substantially fewer genes were commonly
differentially expressed (i.e., co-regulated) in trNK cells in lung
and CD8+ TRM cells in spleen (Fig. 3c). The analysis also revealed
a number of genes that were differentially expressed in opposite
direction in lung and bone marrow trNK cells, including S1PR5,
SMAD3 (↓ in lung, ↑ in bone marrow), ZNF683, CD82, ANXA2,
and several HLA class II-encoding genes (↑ in lung, ↓ in bone
marrow) (Fig. 3a).
To further investigate to what extent gene expression
patterns were shared or differed across trNK cells in lung,
trNK cells in bone marrow, CD8+ TRM cells in lung and CD8+
TRM cells in spleen, we selected genes that were differentially
expressed in trNK cells in lung and in at least one of the
other cell types. Out of the differentially expressed genes (padj
< 0.05, log2 fold change > 1) in CD69+CD49a+CD103+CD16−
trNK cells in lung, 102 genes were also found to be
differentially expressed in trNK cells in bone marrow, CD8+
TRM cells in lung, and/or CD8+ TRM cells in spleen (Fig. 3d).
Eight genes were differentially expressed across all trNK cells
and CD8+ TRM cells, compared to their non-tissue-resident
counterparts: SELL, ITGAE, CXCR6, RGS1, KLF3, FGFBP2,
RAP1GAP2, and RIPOR2 (Fig. 3d, highlighted with red
text). In addition, 35 of the differentially expressed genes in
trNK cells in lung were also differentially expressed in the same
direction in trNK cells in bone marrow, but not in any of the
CD8+ TRM cell subsets (Fig. 3d, highlighted with blue text);
e.g., CCL5, IKZF3, GPR183, IL7R, IL18RAP, IL18R1, ITGAX,
and CD55. Conversely, trNK cells and CD8+ TRM cells in lung
shared 23 differentially expressed genes that were not
differentially expressed in the same direction in trNK cells in
bone marrow; e.g., ZNF683, KLF2, S1PR5, KLRF1, RBPJ,
SAMSN1, and TGFBR3 (Fig. 3d, highlighted with green text).
In addition to the comparisons above, we also compared the
gene expression signature of CD69spCD16− NK cells in lung
with that of trNK cells in bone marrow (Supplementary Fig. 4).
Indeed, most of the differentially expressed genes in
CD69spCD16− NK cells in lung, albeit not many, were also
found to be differentially expressed in trNK cells in bone marrow
(Supplementary Fig. 4a). However, CD69spCD16− NK cells in
lung differed in their expression pattern of a number of genes
associated with tissue-residency, e.g., S1PR5, KLF2/3, ZNF683,
RGS1, and RIPOR2, compared to CD69+CD49a+CD103−CD16−
and CD69+CD49a+CD103+CD16− NK cells (Supplementary
Fig. 4b), indicating that they have a less distinct tissue-resident
phenotype.
Taken together, the comparisons revealed a set of core-genes
that identify but also segregated trNK cells and CD8+ TRM cells
across tissues and cell types, and further highlighted gene
expression patterns shared between trNK cells between tissues.
These findings suggest that gene expression signatures in tissue-
resident lymphocyte subsets are imprinted by the local environ-
ments in the respective tissues as well as being dictated by
cell type.
Stimulated lung trNK cells upregulate effector functions. We
have previously shown that human lung NK cells are hypofunc-
tional in response to target cell stimulation, e.g., with low
degranulation capacity. However, lung NK cells do exhibit a clear
capacity to produce cytokines7. We here set out to extend this
functional analysis to the level of specific subsets of trNK cells in
the human lung. We first show that human lung CD69+
CD49a+ CD103−CD16− and CD69+CD49a+CD103+CD16−
NK cells are functionally equipped at a transcriptional level with
respect to expression of LAMP1, IFNG, TNFA, CCL3, CCL4,
CCL5, and CSF2 (Fig. 4a). Notably, both CD69+CD49a+
CD103−CD16−and CD69+CD49a+CD103+CD16− NK cells
expressed higher levels of CCL5 in comparison to CD69−CD16−,
CD69spCD16−, and CD56dimCD57−NKG2A+ NK cells (Fig. 4a),
suggesting a specific role for human lung trNK cells in production
of CCL5 (RANTES) in the human lung. Furthermore, we iden-
tified elevated CCL3 (MIP-1α) and CSF-2 (GM-CSF) gene
expression levels in CD69spCD16−lung NK cells (Fig. 4a).
At the protein level, CD49a+ lung NK cells (representing the
majority of NK cells with a tissue-resident phenotype in lung)
displayed similar functional capacities upon stimulation with
PMA/ionomycin as CD49a− NK cells, albeit with elevated
observed production of GM-CSF (Fig. 4b, c). Further analysis
of sorted CD16− NK cells revealed that CD49a+CD103+CD16−
NK cells degranulated less and produced less GM-CSF as
compared to CD49a+CD103−CD16− NK cells, whereas TNF
production was similar between the compared subsets (Fig. 4d).
These data thus suggest that functional differences exist even
among NK cells with a tissue-resident phenotype.
IL-15 is a cytokine crucial for development, maintenance and
function of NK cells and TRM cells10,24–26. It is produced at
high levels by dendritic cells27, epithelial cells, and alveolar
macrophages28–30 following viral infections in the lung. Given
the importance of IL-15 for NK cell and TRM cell function, as
well as the potential importance of trNK cells in anti-viral
responses in the lung, we also analyzed different subsets of NK
cells in human lung with respect to responses to IL-15.
Stimulation of sorted CD49a+CD16−, CD49a−CD16−, and
CD16+ lung NK cell subsets with IL-15 for three days resulted
in increased proliferation as indicated by elevated Ki67
expression in both CD49a+CD16− and CD49a−CD16− NK
cells as compared to CD16+ NK cells (Fig. 4e, f). Furthermore,
both CD49a−CD16− NK cells and CD49a+CD16− NK cells
strongly upregulated expression of perforin and granzyme B
following three days of stimulation with IL-15 (Fig. 4e, f).
Notably, these effector molecules were low or virtually
undetectable, respectively, following ex vivo analysis of the
cells (Figs. 2f and 4e, f). In contrast, CCL5 was expressed in
approximately 50% of CD16+ and of CD49a+CD16− NK
cells even in a resting state, whereas CD49a−CD16−NK
cells largely lacked CCL5 expression ex vivo. However, the
CD49a−CD16−NK cells upregulated CCL5 expression to levels
similar to that of CD49a+CD16− NK cells upon in vitro
stimulation with IL-15 (Fig. 4e, f). While CD16+ NK cells were
highly polyfunctional but poorly proliferative, CD49a+CD16−
NK cells made up the dominant polyfunctional subset following
stimulation with IL-15 (Fig. 4g). In contrast, CD49a−CD16−
NK cells were oligofunctional and poised towards perforin
production.
Stimulation with IL-15 also induced de novo CD49a expression
on sorted CD49a−CD16− NK cells derived from the human lung
(Supplementary Fig. 5a), in line with a recent report of
CD49a−induction on peripheral blood-derived NK cells31. The
de novo-induced CD49a+ NK cells also upregulated Ki67,
perforin, granzyme B, and CCL5 (Supplementary Fig. 5b–d) to
a greater extent than CD49a− NK cells. The upregulation of
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CD49a highlights the need to be cautious when analyzing this
response after IL-15 stimulation of bulk NK cells, since de novo
CD49a-expressing NK cells could be confounded with bona fide
CD49a+ NK cells. Finally, the induction of CD49a on NK cells
could indicate that IL-15 plays a role in aiding establishment of
tissue-residency in NK cells upon local increase in IL-15
production during viral infections, as has previously been
proposed for CD8+ TRM cells10,32.
Taken together, the present analysis of CD49a+ NK cells,
representing the vast majority of trNK cells in human lung,
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reveals that they per se are functional and furthermore are able to
upregulate molecules associated with effector functions upon
stimulation with IL-15.
Discussion
There is a growing appreciation that immune cells located in
tissues are of key importance in the defense against infections and
malignant cells. A better understanding of the nature of tissue-
resident lymphocytes, including trNK cells, is therefore not only
of importance from a basic scientific standpoint, but also for
future development of therapies targeting, or in other ways
therapeutically exploiting, these cells. Here, we show that CD16−
NK cells in the human lung encompass a heterogeneous popu-
lation of cells. The population contains distinct subsets of NK
cells displaying hallmarks of tissue-residency, including expres-
sion of CD49a and CD103. Transcriptomic analysis of these
subsets revealed that they have a unique transcriptional profile
with respect to genes regulating tissue-residency, homing and
function. Furthermore, comparative analysis of gene expression-
profiles in trNK cells derived from lung and bone marrow, as well
as CD8+ TRM cells from lung and spleen, revealed that gene
expression patterns regulating tissue-resident lymphocytes are
likely imprinted by the local environments in the respective tis-
sues as well as by cell type.
Our analysis revealed that CD69sp, CD69+CD49a+CD103−
CD16−, and CD69+CD49a+CD103+CD16− NK cell subsets had
increasingly stronger tissue-resident gene expression signatures,
when compared to CD69−CD16− NK cells. For example, the
differences in expression of genes co-regulated across trNK cells
and CD8+ TRM cells in different tissues (Fig. 3d), e.g., SELL,
KLF3, RGS1, RIPOR2, and RAP1GAP2, were gradually increased
when comparing CD69spCD16−, CD49a+CD103−CD16−, and
CD49a+CD103+CD16− NK cells with CD69−CD16− NK cells
(Fig. S4b). This indicates that there might be different stages of
tissue-residency, possibly a reflection of maturation, among trNK
cells. Furthermore, the expression patterns of CD69, CD49a and
CD103 might also translate to different localization of distinct
trNK cell subsets in lung. For example, E-cadherin, the ligand for
CD103, and collagen IV, the ligand for CD49a, are expressed by
epithelial cells lining the alveolar structures in the lung, and the
underlying basement membrane33, respectively. Human CD103+
CD8+ TRM cells have previously been shown to be located within
the lung epithelium14, suggesting that expression of CD103 is
indeed indicative of an intraepithelial localization within the
lung. In addition, CD69+CD103+CD8+ TRM cells are the major
CD8+ T cell subset in epidermis, whereas CD69+CD103−CD8+
TRM cells dominate in dermis of human skin25,34, further sup-
porting the notion that subsets of tissue-resident lymphocytes
have distinct localization. It is thus likely that the CD103+ trNK
cells have an intraepithelial location in the lung and are spatially
separated from the CD49a+CD103−CD16− and CD69spCD16−
NK cells, although the exact localization of the different trNK cell
subsets in human lung remains to investigated.
Both CD69+CD49a+CD103− and CD69+CD49a+CD103+
trNK cells expressed CXCR3 and CXCR6. CXCR6 has previously
been shown to be also expressed by trNK cells in human liver and
bone marrow18,22. The ligand for CXCR6, the chemokine
CXCL16, is produced by alveolar macrophages in high amounts
as observed both in health and in different conditions of dis-
ease35. Thus, CXCR6 might not be unique for homing of NK cells
to the liver or bone marrow but might also mediate NK cell
homing to the lung. Indeed, expression of CXCR6 was also sig-
nificantly upregulated by CD8+ TRM cells in human lung and
spleen (Fig. 3d)1, suggesting a general role of CXCR6 in the
homing to several tissues. In addition to CXCR6, several murine
models suggest a role for CXCR3 in the migration of T cells and
NK cells to the lung under steady-state levels, viral infection, and
non-infectious lung-injury36–38, and antigen-specific CD8+
T cells in bronchoalveolar lavage (BAL) fluid were homogenously
CXCR3hiCD49a+36. Although not much is known about the
contribution of CXCR3-mediated tissue infiltration by NK cells,
CXCR3 is co-expressed on murine CD69+ NK cells in several
tissues39. CXCR3 has also been shown to be crucial for the
migration of NK cells towards and into solid tumors, which
produce high levels of ligands for CXCR340,41. Furthermore, we
recently demonstrated a slight but detectable upregulation of
CD49a on CXCR3+ NK cells on human peripheral blood NK
cells upon acute infection with influenza A virus42. Thus, both
CXCR3 and CXCR6 might be involved in the homing of NK cells
to the human lung and may, therefore, be important for the
generation of a trNK cell population in peripheral tissues
(including the liver and lung) as well as in lymphoid tissue (e.g.,
the bone marrow).
Our comparison of differentially expressed genes with pub-
lished data from trNK cells in bone marrow and CD8+ TRM
cells in lung and spleen revealed that although trNK cells in
lung had a distinct transcriptional profile, they also shared sets
of genes with the other tissue-resident NK cells and T cells. The
finding that all subsets shared a core of differentially expressed
genes, including SELL, S1PR1, CXCR6, RGS1, and KLF3, indi-
cates that these genes regulate tissue-residency across cell types
and tissue locations. Interestingly, the CD69+CD49a+CD103+
trNK cell subset in the lung also shared largely distinct sets of
genes with trNK cells in bone marrow and with CD8+ TRM cells
in lung, respectively. This indicated that both the environment
and cell lineage dictate gene expression patterns in tissue-
resident lymphocytes. Furthermore, the expression of a set of
genes was remarkably different between trNK cells in lung
and bone marrow, including the expression of ZNF683
and CD82 (↑ in lung, ↓ in bone marrow), and S1PR5 and
SMAD3 (↓ in lung, ↑ in bone marrow). Taken together, these
Fig. 3 Human lung trNK cells are distinct from trNK cells in bone marrow and CD8+ TRM cells. Log2 fold-change (log2FC) for differentially expressed genes
(padj < 0.05) detected between CD69+CD49a+CD103+NKG2A+CD16− trNK cells versus CD69−NKG2A+CD16− NK cells in lung plotted against
a log2FC for trNK cells vs CD56bright NK cells in bone marrow, b against CD8+ TRM cells vs TEM cells in lung, and c against CD8+ TRM cells vs TEM cells in
spleen. Data for CD8+ T cells in lung and spleen are from GSE949641 and data for NK cells in bone marrow are from GSE11617820. In total, 13320 genes
detectable above threshold in all datasets were compared. Significantly differentially expressed genes (DEGs) (padj. < 0.05) detected in lung trNK cells
only are depicted in black, while DEGs genes shared with the compared subsets are highlighted in green. DEGs significant in both sets but in opposite
direction are depicted in orange. d Heatmap displaying log2FC of 101 DEGs (padj < 0.05, log2FC > 1) in lung CD69+CD49a+CD103+NKG2A+CD16− NK
cells that were also significantly differentially expressed in at least one of the other 3 subsets analyzed (trNK cells in bone marrow and CD8+ TRM cells in
lung and spleen). Gene names in red depicts DEGs shared across all cell types, orange depicts DEGs shared between trNK cells in lung and bone marrow
and CD8+ TRM cells in lung, dark blue depicts DEGs shared between trNK cells in lung and bone marrow, but not with CD8+ TRM cells in lung and spleen,
and green depicts DEGs shared between trNK cells and CD8+ TRM cells in lung, but not with trNK cells in bone marrow. Gene names in black depicts DEGs
significant in trNK cells in bone marrow or in CD8+ TRM cells, but in opposite direction to trNK cells in lung
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findings further strengthen the notion of the specific tissue
location as a factor involved in dictating the transcriptional
profile of tissue-resident lymphocytes.
Lung trNK cells were prone to produce CCL5, MIP-1β, and
GM-CSF, which might fundamentally alter their local micro-
environment by attracting other immune cells such as monocytes,
T cells, and eosinophils. Indeed, CCR5, the receptor for MIP-1β
and CCL5, is required for efficient CD8+ T cell recruitment to the
lung airways upon viral infection43, and GM-CSF is critical for
terminal differentiation and function of alveolar macrophages44.
Thus, lung trNK cells might have both pro- and anti-
inflammatory influences in respiratory diseases, depending on
the effector molecules they produce. Immune activation in the
lung during, e.g., viral infection results in elevated levels of IL-15
in the tissue but not in the serum, as demonstrated in influenza
infection models45,46. IL-15 is a crucial cytokine for lung T cell
and NK cell survival, activation, and formation of long-lived TRM
cells10,28,46. Hence, IL-15 may have a key role also for lung trNK
cell activation during viral infections. Indeed, we demonstrate
that human lung trNK cells respond strongly towards stimulation
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with IL-15 and become polyfunctional. Furthermore, de novo IL-
15-induced CD49a+CD16− lung NK cells were highly responsive,
possibly promoting the generation and discrete activation of trNK
cells in the lung upon local exposure to IL-15 during, e.g., viral
infection.
In summary, our data demonstrate that human lung CD69+
CD49a+CD103− and CD69+CD49a+CD103+ trNK cells are
clearly distinct from other NK cell subsets in the lung and other
tissues, whereas CD69spCD16− NK cells (lacking expression of
CD49a and/or CD103) are more similar to conventional
CD69−CD16− NK cells. Furthermore, lung trNK cells are func-
tionally competent and, as such, likely to constitute a first line
of defense in the human lung. Together, our characterization of
trNK cells in the human lung provides a basis for future studies of
these cells in respiratory disease development, progression, and
treatment.
Methods
Patients. Tissue samples from a total of 112 patients undergoing lobectomy for
suspected lung cancer were collected in the present study. None of the patients
received preoperative chemotherapy and/or radiotherapy. Patients with records of
strong immunosuppressive medication and/or hematological malignancy were
excluded from tissue sampling. The regional review board in Stockholm approved
the study, all relevant regulations for work with human participants were complied
with, and patient samples were obtained according to the Declaration of Helsinki.
All donors gave informed written consent prior to surgery for sample collection.
Clinical and demographic details of patients are summarized in Table 1.
Processing of tissue specimens and peripheral blood. A small part of macro-
scopically tumor-free human lung tissue from each patient was transferred into ice-
cold Krebs-Henseleit buffer and stored on ice for less than 18 h until further
processing. The tissue was digested using collagenase II (0.25 mg/ml, Sigma-
Aldrich) and DNase (0.2 mg/ml, Roche), filtered and washed in complete RPMI
1640 medium (Thermo Scientific) supplemented with 10% FCS (Thermo Scien-
tific), 1 mM L-glutamine (Invitrogen), 100 U/ml penicillin, and 50 μg/ml strepto-
mycin (R10 medium). Finally, mononuclear cells from the lung cell suspensions
and matched peripheral blood were isolated by density gradient centrifugation
(Lymphoprep).
Flow cytometry. Antibodies and clones reactive against the following proteins
were used (target, clone, fluorochrome, catalog number, dilution): CD3 (UCHT1,
PE/Cy5, Beckman Coulter, #A07749, 1/50), CD8 (RPA-T8, Brilliant Violet 570,
Biolegend, #301038, 1/50), CD14 (MφP9, Horizon V500, BD Biosciences, #561391,
1/100), CD16 (3G8, Brilliant Violet 711, #302043, 1/50 or Brilliant Violet 785,
#302046, 1/200, both Biolegend), CD19 (HIB19, Horizon V500, BD Biosciences,
#561121, 1/100), CD45 (HI30, Alexa Fluor 700, Biolegend, #304024, 1/200), CD49a
(TS2A, Alexa Fluor 647, Biolegend, #328310, 1/25), CD56 (N901, ECD, Beckman
Coulter, #A82943, 1/50, or HCD56, Brilliant Violet 711, Biolegend, #318336. 1/
100), CD57 (TB01, purified, eBioscience, #16-0577, 1/100), CD103 (B-Ly7, APC,
eBioscience, #17-1038-41, 1/50, or 2G5, biotin, Beckman Coulter, #IM0629, 1/50,
or Ber-ACT8, Brilliant Violet 711, BD Biosciences, #563162, 1/50, or Ber-ACT8,
PE/Cy7, Biolegend, #350212, 1/50), NKG2A (Z1991.10, APC-A780, Beckman
Coulter, custom conjugation, 1/25), CD69 (TP1.55.3, ECD, Beckman Coulter,
#6607110, 1/50), CD127 (HIL-7R-M21, Brilliant Violet 421, BD Biosciences,
#562436, 1/50 or R34.34, PE/Cy7, Beckman Coulter, #FA64618, 1/25), CXCR3
(G025H7, PE/Cy7, Biolegend, #353720, 1/25), CXCR6 (K041E5, Brilliant Violet
421, Biolegend, #151109, 1/50), KIR2DL1/S1 (EB6, Beckman Coulter, #A66898, 1/
25) and KIR2DL2/3/S2 (GL183, PE/Cy5.5, Beckman Coulter, #A66900, 1/25). After
two washes, cells were stained with streptavidin Qdot 605 or Qdot 585 (both
Invitrogen), anti-mouse IgM (II/41, eFluor 650NC, eBioscience, #95-5790-42, 1/
200) and Live/Dead Aqua (Invitrogen). After surface staining, peripheral blood
mononuclear cells (PBMC) were fixed and permeabilized using FoxP3/Tran-
scription Factor staining kit (eBioscience). For intracellular staining the following
antibodies were used: Eomes (WF1928, FITC, eBioscience, #11-4877-42, 1/50),
CCL5 (2D5, Brilliant Violet 421, BD Biosciences, #564754, 1/25), GM-CSF (BVD2-
21C11, PE-CF594, BD Biosciences, #562857, 1/50), granzyme B (GB11, Alexa Fluor
647, BD Biosciences, #560212, 1/50), IFN-γ (4 S.B3, Brilliant Violet 570, Biolegend,
#502533, 1/25), Ki67 (B56, FITC, BD Biosciences, #556026, 1/100), MIP-1β (D21-
1351, PE, BD Biosciences, #550078, 1/50), perforin (dG9, FITC, BD Biosciences,
#556577, 1/50), T-bet (4B10, Brilliant Violet 421, #644816, 1/50 or O4-46, PE-
CF594, BD Biosciences, #562467, 1/50), and TNF (MAb11, PE/Cy7, Biolegend,
#502929, 1/50). Samples were analyzed on a BD LSR Fortessa equipped with four
lasers (BD Biosciences), and data were analyzed using FlowJo version 9.5.2 (Tree
Star Inc).
Fig. 4 Human lung trNK cells are functional upon stimulation. a Counts per million (CPM) reads for selected genes in human lung CD69−NKG2A+CD16−
(dark grey), CD69spNKG2A+CD16− (orange), CD69+CD49a+CD103−NKG2A+CD16−(light blue), and CD69+CD49a+CD103+NKG2A+
CD16−(dark blue) NK cells. CD56dimCD16+CD57−NKG2A+ NK cells (light grey) are shown for comparison. Two biological replicates from two donors are
shown. Mean ± SEM is shown. b Representative histograms and c summary of data for degranulation and cytokine production of PMA/ionomycin-
stimulated lung NK cells. CD49a− and CD49a+ NK cells were gated, and background responses in unstimulated controls were subtracted (CD107a, n= 4;
GM-CSF, n= 6; IFN-γ, n= 5; MIP-1β, n= 6; TNF, n= 5). Box and Whiskers, min to max with central line indicating the median and individual data points
shown, the mean is indicated as ‘+ ’. Wilcoxon matched-pairs signed rank test, *p < 0.05. Numbers in b indicate percentage of marker-positive NK cells.
d Degranulation and cytokine production by sorted CD16− and CD16+ human lung NK cells after PMA/ionomycin stimulation. CD49a and CD103 were
used to identify distinct NK cell subsets (n= 3) after stimulation. e Representative overlays and f summary of data for expression of Ki67, perforin,
granzyme B, and CCL5 in sorted CD16+, CD16−CD49a−, and CD16−CD49a+ lung NK cells, respectively, following stimulation with IL-15 for 3 days.
(n= 4). Mean ± SD is shown. n.a.= not analyzed. The majority of the sorted CD16−CD49a+ NK cells also co-expressed CD103. Numbers in e indicate
percentage of marker-positive NK cells. g SPICE analysis for proliferation and effector molecule expression in sorted CD16+, CD16−CD49a−, and
CD16−CD49a+ lung NK cell subsets following stimulation with IL-15 for 3 days (n= 3). Floating bars, min-max. Individual data points are shown. Source
data are provided as a Source Data file
Table 1 Clinical and demographic details of the 112 patients
included in the study
Non-
smoker
(n= 14)
Current
smoker
(n= 29)
Ex-smoker
(n= 69)
Female/male 9 / 5 16 / 13 44 / 25
Age (year), mean ± SD 68 ± 12.3 66 ± 9 68 ± 8.8
FEV1/FVC (% of predicted)
mean ± SD
103 ± 8.8a 91 ± 13.8b 96 ± 14c
Pathology % (n) % (n) % (n)
Non-malignant 7 (1) 3 (1) 4 (3)
Adenocarcinoma 50 (7) 62 (18) 71 (49)
Large cell carcinoma 0 (0) 10 (3) 4 (3)
Squamous cell carcinoma 0 (0) 10 (3) 9 (6)
Metastasis 14 (2) 3 (1) 4 (3)
Carcinoid 29 (4) 7 (2) 6 (4)
Other 0 (0) 3 (1) 1 (1)
Medication % (n) % (n) % (n)
Inhaled corticosteroids alone 14 (2) 0 (0) 1 (1)
Statins 43 (6) 21 (6) 25 (17)
Systemic immunosuppression 0 (0) 0 (0) 4 (3)
Beta-agonists or anti-
cholinergics
0 (0) 7 (2) 12 (8)
Inhaled corticosteroid and
long-acting beta-agonist
combination
14 (2) 7 (2) 6 (4)
an= 13
bn= 27
cn= 66
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For cell sorting experiments for RNA sequencing thawed cryopreserved lung
mononuclear cells were stained with anti-human CD57 (NK-1, FITC, BD
Biosciences, #555619, 1/25), CD16 (3G2, Pacific Blue, BD Biosciences, #558122,
1/50), CD14 (MφP9, Horizon V500, BD Biosciences, #561391, 1/100), CD19
(HIB19, Horizon V500, BD Biosciences, #561121, 1/100), CD103 (Ber-ACT8,
Brilliant Violet 711, BD Biosciences, #563162, 1/50), CD49a (TS2/7, AlexaFluor
647, Biolegend, #328310, 1/25), CD45 (HI30, Alexa Fluor 700, Biolegend,
#304024, 1/200), CD8 (RPA-T8, APC/Cy7, BD Biosciences, #557834, 1/25),
NKG2A (Z199.10, PE, Beckman Coulter, #IM3291U, 1/50), CD69 (TP1.55.3,
ECD, Beckman Coulter, #6607110, 1/50), CD3 (UCHT1, PE/Cy5, Beckman
Coulter, #A07749, 1/50), KIR2DL1/S1 (EB6, PE/Cy5.5, Beckman Coulter,
#A66898, 1/25), KIR2DL2/3/S2 (GL183, PE/Cy5.5, Beckman Coulter, #A66900,
1/25), NKG2C (134591, biotin, R&D Systems, custom conjugate, 1/50), CD56
(NCAM16.1, PE/Cy7, BD Biosciences, #557747, 1/50), streptavidin Qdot655
(Invitrogen), and Live/Dead Aqua (Invitrogen). For cell sorting experiments for
functional assays, thawed cryopreserved lung mononuclear cells were stained
with CD3 (UCHT1, PE/Cy5, Beckman Coulter, #A07749, 1/50), CD14 (MφP9,
Horizon V500, BD Biosciences, #561391, 1/100), CD16 (3G8, APC/Cy7, BD
Biosciences, #557758, 1/50), CD19 (HIB19, Horizon V500, BD Biosciences,
#561121, 1/100), CD45 (HI30, Alexa Fluor 700, Biolegend, #304024, 1/200),
CD49a (TS2/7, PE/Cy7, Biolegend, #328311, 1/50), CD56 (N901, PE/Cy5.5,
Beckman Coulter, #A79388, 1/50), CD103 (Ber-ACT8, Brilliant Violet 711, BD
Biosciences, #563162, 1/50), and Live/Dead Aqua (Invitrogen). Cells were sorted
on a FACSAria Fusion (BD Biosciences).
Functional analysis of lung NK cells. In one set of experiments, lung cells were
cultured in the absence or presence of phorbol 12-myristate 13−acetate (PMA,
10 ng/ml) and ionomycin (500 nM) for 4 h. Monensin and brefeldin A (GolgiPlug/
Stop, BD Biosciences) were added for the last 3 h of incubation. Anti-human
CD107a (FITC, H4A3; BD Biosciences, #555800, 1/100) was present throughout
the assay. Finally, cells were stained and analyzed by flow cytometry, as described
above. In another set of experiments, sorted lung and blood NK cell subsets were
cultured in the presence or absence of IL-15 (10 ng/ml) (Peprotech) for 3 days,
followed by staining and analysis by flow cytometry.
Preparation of libraries for RNA sequencing. RNAseq was performed using a
modified version of the SMART-Seq2 protocol47. Four subsets of live, CD3-CD14−
CD19−CD56+NKG2A+CD16− NK cells were sorted: CD69−CD49a−CD103−
(CD69−), CD69+CD49a−CD103− (CD69sp), CD69+CD49a+CD103−, and
CD69+CD49a+CD103+. CD56dimCD16+NKG2A+CD57− NK cells were sorted as
a reference. Duplicates of 100 cells from each population from two individual
donors were sorted into 4.2 μl of lysis buffer (0.2% Triton X-100, 2.5 μM oligo-dT
(5′-AAGCAGTGGTATCAACGCAGAGTACT30VN-3′), 2.5 mM dNTP, RNAse
Inhibitor (Takara), and ERCC RNA spike in controls (Ambion)) in a 96-well V-
bottom PCR plate (Thermo Fisher). Sorted cells were then frozen and stored at
−80 °C until they could be processed. Subsequent steps were performed following
the standard SMART-Seq2 protocol with 22 cycles of cDNA amplification and
sample quality was determined using a bioanalyzer (Agilent, High Sensitivity DNA
chip). Five nanograms of amplified cDNA was taken for tagmentation using a
customized in-house protocol48 and Nextera XT primers. Pooled samples were
sequenced on a HiSeq2500 on high output mode with paired 2 × 125 bp reads.
Transcriptome analysis. Following sequencing and demultiplexing, read pairs
were trimmed from Illumina adapters using cutadapt (version 1.14)49, and UrQt
was used to trim all bases with a phred quality score below 2050. Read pairs were
subsequently aligned to the protein coding sequences of the human transcriptome
(gencode.v26.pc_transcripts.fa) using Salmon (version 0.8.2)51, and gene annota-
tion using gencode.v26.annotation.gtf. DeSeq252 was used to analyze RNA-seq data
in R studio version 1.20. Briefly, averaged raw count values for biological replicates
were used as input into deSeq2, and variance stabilizing transformation was used to
transform data. Data were batch- and patient corrected using Limma53. A cut-off
of > 100 counts for the four subsets among the 15 samples was used to filter out low
expressed genes. Genes with an adjusted p-value < 0.05 and a log2-fold change
greater than 1 were considered as differentially expressed between paired samples.
Similarly, previously published data sets on trNK cells in bone marrow
(GSE116178)20 and on CD8+ TRM cells in lung and spleen (GSE94964)1 were
analyzed using deSeq2 to identify differentially expressed genes. Heatmaps of gene
expression were generated using Pheatmap in R and show z-score for differentially
expressed genes (as determined above in deSeq2) for all donors and replicates.
Euler diagrams were generated by the eeuler-package in R.
Statistics. GraphPad Prism 6 and 7 (GraphPad Software) were used for statistical
analysis. For each analysis, measurements were taken from distinct samples. The
statistical method used is indicated in each figure legend.
Data availability
The read counts for the RNA sequencing data derived from lung NK cells is available at
GEO with accession number GSE130379. RNA sequencing data for trNK cells in bone
marrow was previously published20 and is available at GEO with accession number
GSE116178. RNA sequencing data for CD8+ TRM cells in lung and spleen was previously
published1 and is available at GEO with accession number GSE94964. All other relevant
data that support the findings of the study are available from the corresponding author
upon reasonable request. The source data underlying Figs. 1b, 1c, 1e–i, 2b, 2d, 2f, 2h, 4a,
4c–d, 4f–g, and Supplementary Figs. S1e, S2a–d, and S5b–d are provided as a Source
Data file.
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